Diagnosis of Osteoporosis in Patients Treated With Statins Is Dose Dependent
The diagnosis of osteoporosis was overrepresented in patients receiving high-dose and underrepresented in patients receiving low-dose statin treatment.
Bone Metabolism
New Treatment Approved for Osteoporosis
The Company is currently conducting a comparative study with the aim of having the treatment designated as a therapeutic equivalent to Forteo.
Recommendations for Secondary Fracture Prevention in Elderly Patients
The American Society for Bone and Mineral Research developed 13 clinical recommendations (7 primary and 6 secondary) to address the undertreatment of osteoporosis-related fractures and prevent secondary fracture among persons aged ≥65 years with hip or vertebral fractures.
Burosumab Approved to Treat X-Linked Hypophosphatemia in Patients as Young as 6 Months
The FDA has expanded the approval of Crysvita (burosumab; Ultragenyx and Kyowa Kirin) to include treatment in pediatric patients as young as 6 months with X-linked hypophosphatemia.
Comparative Efficacy of Medications for Glucocorticoid-Induced Fracture Prevention
A meta-analysis found that teriparatide and denosumab may be the most efficacious therapy for prevention of glucocorticoid-induced vertebral fractures.
How Do GLP-1 Levels Relate to Osteoporosis in Postmenopausal Women?
High GLP-1 levels were associated with reduced risk for osteoporosis in postmenopausal women.
Positive Patient Experience With Abaloparatide in Osteoporosis
The study, presented at the American Society for Bone and Mineral Research 2019 Annual Meeting, described the experience of patients who initiated treatment with abaloparatide.
Genetically Increased Serum Calcium Not Linked to Improved BMD, Reduced Fracture Risk
Researchers assessed the effect of genetically predicted higher serum calcium levels on bone mineral density and the risk for fracture, using Mendelian randomization.
Improved Safety Outcomes With Twice-Weekly vs Once-Weekly Teriparatide in Osteoporosis
Researchers investigated the safety and efficacy of twice-weekly 28.2 μg teriparatide compared with once-weekly 56.5 μg teriparatide in Japanese patients with osteoporosis.
Does Calcium Supplementation Affect Risk for Abdominal Aortic Calcification?
Long-term use of calcium supplements is not associated with increased risk for development or progression of abdominal aortic calcification in older women.
Next post in ASBMR 2019
